Stock comparison
Avantor, Inc. is 1.2x more valuable than 10x Genomics, Inc. by market capitalization ($10.23 B vs $8.38 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
AVTR is larger
Avantor, Inc. is 1.2x more valuable than 10x Genomics, Inc. by market capitalization ($10.23 B vs $8.38 B).
Market value leader
AVTR
Avantor, Inc. is 1.2x more valuable than 10x Genomics, Inc. by market capitalization ($10.23 B vs $8.38 B).
Revenue leader
AVTR
TXG: $642.82M vs AVTR: $6.55B.
Profit leader
TXG
TXG: -$43.50M vs AVTR: -$530.20M.
Margin leader
TXG
TXG: -6.8% vs AVTR: -8.1% net margin.
| Metric | TXG | AVTR |
|---|---|---|
| Market cap | $8.38 B | $10.23 B |
| US-listed rank | #1067 | #932 |
| Revenue (latest FY) | $642.82M | $6.55B |
| Net income (latest FY) | -$43.50M | -$530.20M |
| Net margin | -6.8% | -8.1% |
| P/E (trailing FY) | - | - |
| SEC filings | 652 | 763 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
Avantor, Inc. is 1.2x more valuable than 10x Genomics, Inc. by market capitalization ($10.23 B vs $8.38 B).
In their latest fiscal years, 10x Genomics, Inc. reported $642.82M in revenue while Avantor, Inc. reported $6.55B.
Full pages: 10x Genomics, Inc. and Avantor, Inc., or browse the full rankings.